Previous 10 | Next 10 |
Natera Files Patent Infringement Suit Against Inivata PR Newswire SAN CARLOS, Calif. , Jan. 20, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, filed a lawsuit today against Inivata, Ltd. and its wholly-...
New Data at the 2021 ASTS Winter Symposium to Showcase Benefit of Serial Prospera™ Testing PR Newswire SAN CARLOS, Calif. , Jan. 14, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, tod...
Natera to Present New Colorectal Cancer Data at the 2021 ASCO GI Symposium Oral presentation showcases the largest early-stage CRC cohort to date, further validating the serial use of Signatera™ for early recurrence detection and MRD assessment PR Newswire S...
It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. And interestingly, some testing companies performed ...
Natera to Webcast Live Presentation at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN CARLOS, Calif. , Jan. 5, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced t...
U.S. Patent Office Upholds Validity of Natera's Early Priority Date '592 cfDNA Patent SAN CARLOS, Calif. , Dec. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, is pleased that the United States Paten...
Increased adoption and expansion of products resulting in significant rises in volume. Producing meaningful improvements in revenues and costs per unit. Confidently raising 2020 guidance. For further details see: Natera: Conceive, Deliver, Thrive
New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial SAN CARLOS, Calif. , Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that n...
Natera to Present New Immunotherapy Monitoring Data at SABCS 2020 SAN CARLOS, Calif. , Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and ...
Natera (NTRA) announces that the second-largest U.S. commercial insurer has extended coverage of non-invasive prenatal tests ((NIPT)) to all singleton pregnancies. The largest player announced the same several days ago.The expanded coverage bodes well for the company's Panorama molecular test...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...